SCHEMBL17029102

SCHEMBL17029102

Cc1nc(Cl)cc(Nc2ncc(COC=O)s2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRNA7 P36544 1/20 0.38
▸ KIT P10721 7/20 0.37
▸ LCK P06239 4/20 0.37
▸ ABL1 P00519 3/20 0.37
▸ SRC P12931 2/20 0.37
▸ MAPK13 O15264 1/20 0.37
▸ EGFR P00533 1/20 0.37
▸ ERBB2 P04626 1/20 0.37
▸ FYN P06241 1/20 0.37
▸ YES1 P07947 1/20 0.37
▸ LYN P07948 1/20 0.37
▸ HCK P08631 1/20 0.37
▸ FGR P09769 1/20 0.37
▸ BCR P11274 1/20 0.37
▸ JAK3 P52333 1/20 0.37
▸ MAPK12 P53778 1/20 0.37
▸ MAPK11 Q15759 1/20 0.37
▸ MAPK14 Q16539 1/20 0.37
▸ SIK2 Q9H0K1 3/20 0.36
▸ SIK3 Q9Y2K2 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28165662 0.80 ABL1 (0.41) CHRNA7KITLCKABL1SRC
SCHEMBL27792012 0.79 LCK (0.42) CHRNA7KITLCKABL1SRC
SCHEMBL27813487 0.76 CHRNA7 (0.37) CHRNA7KITLCKABL1SRC
SCHEMBL17029103 0.74 L3MBTL1 (0.33) L3MBTL1
SCHEMBL4254631 0.72 ABL1 (0.50) KITLCKABL1SRCMAPK13
SCHEMBL21495194 0.72 SIK2 (0.48) KITLCKABL1SRCMAPK13
SCHEMBL4254834 0.72 LCK (0.52) KITLCKABL1SRCMAPK13
SCHEMBL20633817 0.72 RAB9A (0.52) KITLCKABL1SRCMAPK13
SCHEMBL12445981 0.72 LCK (0.52) CHRNA7KITLCKABL1SRC
SCHEMBL27792010 0.71 LCK (0.42) CHRNA7KITLCKABL1SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150259337-A1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF DASATINIB CERBIOS-PHARMA SA (CH) 2015-09-17 — — US disclosed
US-9115124-B1 Process and intermediates for the preparation of dasatinib CERBIOS-PHARMA SA (CH) 2015-08-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259337-A1 PROCESS AND INTERMEDIATES FOR THE PREPARATION OF DASATINIB ABL1, SRC, ABL2 CHRNA7 4867/4885KIT 792/4885LCK 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback